MaxCyte awarded US patent
MaxCyte, a biotechnology company developing cell-based therapeutics and technologies, has been awarded US patent no. 6,773,669, entitled 'Flow Electroporation Chamber and Method', from the US patent and trademark office.
MaxCyte, a biotechnology company developing cell-based therapeutics and technologies, has been awarded US patent no. 6,773,669, entitled 'Flow Electroporation Chamber and Method', from the US patent and trademark office.
The patent broadly covers any electroporation system that incorporates a computer to control, for example, the flow of biological materials through the electroporation chamber, or other aspects of electroporation, such as electrical pulsing parameters.
The patent complements and expands MaxCyte's intellectual property position in the US, Europe and other countries, which includes claims to various electroporation system designs and processes, as well as the company's unique flow-based technology.
Electroporation - the use of electric current to make cell membranes permeable and thereby allow the introduction of new DNA or other molecules - is a technology that, in its static form, has been used in research settings for decades.
By loading cells in a flow process and automating the system by computer, MaxCyte has refined electroporation in order to vastly increase the volume, efficiency and viability of cells loaded so that the technology can be used for rapidly developing cell-based therapeutics and biotherapeutic manufacturing.
MaxCyte's closed and sterile clinical grade system is amenable to multiple applications, including the introduction of nucleic acids (genes, siRNA), drugs or proteins to any cell type and ex vivo gene delivery.